CNR1 and Alzheimer disease: To date, extensive research has explored the effects of pharmacological modulation of the ECS, demonstrating that activation of specific CB1 and CB2 receptors decreases the accumulation and deposition of Aβ plaques, reduces neuroinflammation, and improves cognitive decline in AD preclinical models [11,25,26,27,28,29].